HC Wainwright Reiterates “Buy” Rating for Poseida Therapeutics (NASDAQ:PSTX)

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $20.00 price target on the stock.

Poseida Therapeutics Trading Up 0.2 %

PSTX stock opened at $2.16 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.18 and a current ratio of 3.18. The company’s 50-day simple moving average is $3.13 and its 200 day simple moving average is $2.94. Poseida Therapeutics has a 52 week low of $1.54 and a 52 week high of $4.27. The company has a market capitalization of $208.42 million, a PE ratio of -1.55 and a beta of 0.36.

Poseida Therapeutics (NASDAQ:PSTX) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 190.76% and a negative return on equity of 94.90%. The business had revenue of $25.00 million for the quarter, compared to the consensus estimate of $12.50 million. As a group, sell-side analysts anticipate that Poseida Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On Poseida Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of PSTX. Allspring Global Investments Holdings LLC acquired a new position in shares of Poseida Therapeutics in the third quarter valued at about $29,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Poseida Therapeutics in the fourth quarter valued at about $36,000. Tower Research Capital LLC TRC grew its stake in shares of Poseida Therapeutics by 110.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,679 shares of the company’s stock valued at $36,000 after acquiring an additional 5,606 shares in the last quarter. Keystone Financial Group acquired a new stake in Poseida Therapeutics during the third quarter worth about $36,000. Finally, Strs Ohio acquired a new stake in Poseida Therapeutics during the third quarter worth about $47,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.